UnitedHealth Group’s ( UNH) new CEO, Stephen Hemsley, is shaking up the senior management of the company, appointing Patrick Conway, newly named CEO of the managed care giant’s Optum unit, as the head ...

US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...

Having to take Ozempic or other weight loss drugs can be a real pain in the ass, with users often having to jab themselves ...

Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

What does the fracturing of vaccine advice and policy mean for the U.S. health care ecosystem? Will the potential head of the ...

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

A new drug, 'MariTide,' developed by Amgen, has shown significant potential in treating obesity, with trial participants losing up to 16% body weight annually.

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.